the cliff
Patent cliff
Drugs ranked by the soonest barrier to generic / biosimilar entry. Each row shows the earliest-expiring patent OR FDA exclusivity for that drug — whichever falls first determines when competitive pressure begins.
- Oct 9, 20282.1ypatentXtampza ERoxycodone$COLLCOLLEGIUM PHARMACEUTICAL, INC
- Oct 10, 20282.1ypatentTruqapcapivasertib$AZNASTRAZENECA PLC
- Oct 11, 20282.1ypatentGLYCOPYRROLATEGLYCOPYRROLATEExela Pharma Sciences LLC
- Oct 11, 20282.1ypatentPred Forteprednisolone acetate$ABBVAbbVie Inc.
- Oct 12, 20282.1yNCEVelsipityetrasimod$PFEPFIZER INC
- Oct 15, 20282.1ypatentLatanoprost GreenstonelatanoprostGreenstone LLC
- Oct 15, 20282.1ypatentNerlynxneratinib$PBYIPUMA BIOTECHNOLOGY, INC.
- Oct 16, 20282.1yNPFerahemeferumoxytolCovis Pharma BV
- Oct 16, 20282.1ypatentPropranolol Hydrochloridepropranolol hydrochloridePar Pharmaceutical Inc
- Oct 17, 20282.1ypatentQbrexzaglycopyrronium tosylate$DERMJourney Medical Corp
- Oct 17, 20282.1yNPPhotrexa Viscousriboflavin 5'-phosphate sodium$GKOSGLAUKOS Corp
- Oct 17, 20282.1yNCEZilbrysqzilucoplanUCB SA
- Oct 22, 20282.1yGAINContepofosfomycin disodium [INN]Meitheal Pharmaceuticals Inc
- Oct 24, 20282.1ypatentTigecyclinetigecyclineMeitheal Pharmaceuticals Inc
- Oct 26, 20282.1yNCEAgamreevamoroloneReveraGen BioPharma Inc
- Oct 27, 20282.1ypatentExondys 51eteplirsen$SRPTSarepta Therapeutics, Inc.
- Oct 30, 20282.1ypatentMyrbetriqmirabegronAstellas Pharma US Inc
- Oct 31, 20282.1ypatentYupelrirevefenacinTheravance Biopharma US Inc
- Oct 31, 20282.1yNCEZurzuvaezuranoloneSage Therapeutics Inc
- Nov 6, 20282.1ypatentTavalissefostamatinib disodium$RIGLRIGEL PHARMACEUTICALS INC
- Nov 7, 20282.1ypatentORIAHNN (COPACKAGED)ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE$ABBVAbbVie Inc.
- Nov 10, 20282.2ypatentCarbamazepinecarbamazepineRiconpharma LLC
- Nov 11, 20282.2ypatentErivedgevismodegibGenentech Inc
- Nov 15, 20282.2yGAINDefencath(heparin sodium + taurolidine [INN])$CRMDCorMedix Inc.
- Nov 15, 20282.2yNCEAugtyrorepotrectinibBristol-Myers Squibb Co
- Nov 16, 20282.2ypatentFotivdativozanib hydrochlorideAVEO Pharmaceuticals Inc
- Nov 19, 20282.2yM-82Igalmidexmedetomidine$BTAIBioXcel Therapeutics, Inc.
- Nov 22, 20282.2yODE-386FyarrosirolimusKaken Pharmaceutical Co Ltd
- Nov 26, 20282.2ypatentZyloprimallopurinolCasper Pharma LLC
- Nov 27, 20282.2yNCEOgsiveonirogacestat hydrobromideSpringWorks Therapeutics Inc
- Dec 5, 20282.2ypatentLoseasoniqueethinylestradiol + levonorgestrelTeva Pharmaceuticals USA Inc
- Dec 8, 20282.2ypatentEllaulipristal acetateHRA Pharma LLC
- Dec 9, 20282.2yGAINRecarbrio(cilastatin sodium + imipenem + relebactam)$MRKMerck & Co., Inc.
- Dec 11, 20282.2yGAINBlujepagepotidacin mesylateGlaxoSmithKline LLC
- Dec 14, 20282.2ypatentCEFIXIMECEFIXIMELupin Ltd
- Dec 15, 20282.3ypatentQutenzacapsaicinGrunenthal GmbH
- Dec 16, 20282.3ypatentCARIPRAZINE HYDROCHLORIDECARIPRAZINE HYDROCHLORIDE$ABBVAbbVie Inc.
- Dec 16, 20282.3yNPRevatiosildenafil citrate$VTRSViatris Inc
- Dec 18, 20282.3yNCEFilsuvezbirch triterpenesChiesi USA Inc
- Dec 19, 20282.3yNPPAccruferferric maltolShield TX (UK) Ltd
- Dec 19, 20282.3yI-979JascaydnerandomilastBoehringer Ingelheim International GmbH
- Dec 21, 20282.3yNCEWainuaeplontersen sodium$AZNASTRAZENECA PLC
- Jan 5, 20292.3yNCEZelsuvmiberdazimer sodium [INN]$PTHSPelthos Therapeutics Inc.
- Jan 5, 20292.3ypatentCopiktraduvelisibSecura Bio Inc
- Jan 7, 20292.3ypatentLAMOTRIGINELAMOTRIGINEIpca Pharmaceuticals Inc
- Jan 21, 20292.4yD-198VerquvovericiguatMerck Sharp & Dohme LLC
- Jan 28, 20292.4yNPYuvezzi(brimonidine tartrate + carbachol [INN])Tenpoint Therapeutics Ltd
- Jan 28, 20292.4ypatentMyfembree(estradiol + norethindrone acetate + relugolix)Sumitomo Pharma America Inc
- Jan 28, 20292.4ypatentOrgovyxrelugolixSumitomo Pharma America Inc
- Feb 3, 20292.4ypatentPROGESTERONEPROGESTERONEIBSA Institut Biochimique SA
sourced from FDA Orange Book · approved drugs only · biologics + biosimilars excluded (those live in the Purple Book — coming soon)